CD133
| View/Edit Human | View/Edit Mouse |
CD133 antigen, also known as prominin-1, is a
transmembrane glycoproteins, which specifically localize to cellular protrusions. When embedded in the cell membrane, the membrane topology of prominin-1 is such that the N-terminus extends into the extracellular space and the C-terminus resides in the intracellular compartment. The protein consists of five transmembrane segments, with the first and second segments and the third and fourth segments connected by intracellular loops while the second and third as well as fourth and fifth transmembrane segments are connected by extracellular loops.[7] While the precise function of CD133 remains unknown, it has been proposed that it acts as an organizer of cell membrane topology.[8]
Tissue distribution
CD133 is expressed in
glial stem cells,[11] various pediatric brain tumors,[12] as well as adult kidney, mammary glands, trachea, salivary glands, uterus, placenta, digestive tract, testes, and some other cell types.[13][14][15]
Clinical significance
Today CD133 is the most commonly used marker for isolation of
immunogenic and can be used as an antimelanoma vaccination. In mice the vaccination with CD133+ melanoma cells mediated strong anti-tumor activity that resulted in the eradication of parental melanoma cells.[22] In addition, it has also been shown that CD133+ melanoma cells preferentially express the RNA helicase DDX3X. As DDX3X also is an immunogenic protein, the same anti-melanoma vaccination strategy can be employed to give therapeutic antitumor immunity in mice.[23]
See also
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000007062 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000029086 - Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- PMID 9389720.
- PMID 11467842.
- PMID 23161072.
- PMID 24093054.
- PMID 10075457.
- PMID 10681530.
- PMID 16120861.
- ^ PMID 14522905.
- S2CID 44681326.
- PMID 15694831.
- PMID 27166505.
- S2CID 90912166.
- PMID 25763821.
- PMID 14645703.
- S2CID 14693017.
- S2CID 25435240.
- PMID 17320377.
- S2CID 25329727.
- S2CID 25347678.
Further reading
- Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y (November 2009). "CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas" (PDF). Pancreas. 38 (8): e207-14. S2CID 25675719. Archived from the original(PDF) on 2018-11-01. Retrieved 2018-10-31.
- Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G (September 2009). "Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment". Proceedings of the National Academy of Sciences of the United States of America. 106 (38): 16281–6. PMID 19805294.
- Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I (February 2010). "CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients". International Journal of Cancer. 126 (4): 950–8. S2CID 23335006.
- Nishide K, Nakatani Y, Kiyonari H, Kondo T (August 2009). Lowenstein PR (ed.). "Glioblastoma formation from cell population depleted of Prominin1-expressing cells". PLOS ONE. 4 (8): e6869. PMID 19718438.
- Na YR, Seok SH, Kim DJ, Han JH, Kim TH, Jung H, Lee BH, Park JH (2009). "Isolation and characterization of spheroid cells from human malignant melanoma cell line WM-266-4". Tumour Biology. 30 (5–6): 300–9. S2CID 40841423.
- Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S, Smith A (2009). Chédotal A (ed.). "CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent". PLOS ONE. 4 (5): e5498. PMID 19430532.
- Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK (July 2009). "Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants". Cancer Prevention Research. 2 (7): 617–24. PMID 19584075.
- Yao J, Zhang T, Ren J, Yu M, Wu G (October 2009). "Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells". Oncology Reports. 22 (4): 781–7. PMID 19724856.
- Yasuda H, Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Kawamoto A, Inoue Y, Miki C, Kusunoki M (October 2009). "Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer". Oncology Reports. 22 (4): 709–17. PMID 19724847.
- Yoshikawa S, Zen Y, Fujii T, Sato Y, Ohta T, Aoyagi Y, Nakanuma Y (October 2009). "Characterization of CD133+ parenchymal cells in the liver: histology and culture". World Journal of Gastroenterology. 15 (39): 4896–906. PMID 19842219.
- Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G (July 2009). "CD133 antigen expression in ovarian cancer". BMC Cancer. 9: 221. PMID 19583859.
- Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J (September 2009). "Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer". Histopathology. 55 (3): 284–93. S2CID 12088193.
- Friedman S, Lu M, Schultz A, Thomas D, Lin RY (2009). Breant B (ed.). "CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin". PLOS ONE. 4 (4): e5395. PMID 19404394.
- Cheng JX, Liu BL, Zhang X (August 2009). "How powerful is CD133 as a cancer stem cell marker in brain tumors?". Cancer Treatment Reviews. 35 (5): 403–8. PMID 19369008.
- Horst D, Kriegl L, Engel J, Kirchner T, Jung A (October 2009). "Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer". Cancer Investigation. 27 (8): 844–50. S2CID 35888000.
- Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC (September 2009). "CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection". BMC Cancer. 9: 324. PMID 19744348.
- Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, Zhang X, Pan ZZ, Wan DS, Zeng YX, Zhu XF, Zhang XS (July 2009). "Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB". Journal of Translational Medicine. 7: 56. PMID 19583834.
- Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y (2009). "CD133 gene overexpression is frequently observed in early colorectal carcinoma". Hepato-Gastroenterology. 56 (93): 995–7. PMID 19760928.
- Pras E, Abu A, Rotenstreich Y, Avni I, Reish O, Morad Y, Reznik-Wolf H, Pras E (August 2009). "Cone-rod dystrophy and a frameshift mutation in the PROM1 gene". Molecular Vision. 15: 1709–16. PMID 19718270.
- Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G (July 2009). "Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors". Clinical Cancer Research. 15 (13): 4299–311. PMID 19509143.
External links
- GeneReviews/NCBI/NIH/UW entry on Retinitis Pigmentosa Overview
- Human PROM1 genome location and PROM1 gene details page in the UCSC Genome Browser.